Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products…
Medical - Devices
US, Irvine [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 11.21 | 3.75 | 3.38 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 18.15 | -1.00 | -1.22 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 7.68 | 11.83 | 10.99 | |
| Cash | 3.85 | 2.82 | 2.72 | |
| Capex | 15.54 | -0.14 | -0.17 | |
| Free Cash Flow | 298.94 | -0.23 | 0.06 | |
| Revenue | 4.80 | 2.66 | 2.53 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -1.01 | 0.76 | 0.77 | |
| Operating Margin | 5.01 | 0.27 | 0.26 | |
| ROA | -8.51 | 0.04 | 0.04 | |
| ROE | -11.12 | 0.05 | 0.06 | |
| ROIC | 1.52 | 0.05 | 0.05 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of EW is permitted for members.
5
Growth
The "Growth Entry" for the Focus of EW is permitted for members.
6
Leverage & Liquidity